共 187 条
[1]
Elstein D(2004)Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease J Inherit Metab Dis 27 757-766
[2]
Hollak C(2007)Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement Blood 110 2296-2301
[3]
Aerts JM(2002)Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease Blood Cells Mol Dis 28 127-133
[4]
van Weely S(2000)Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis Lancet 355 1481-1485
[5]
Maas M(2007)Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study Lancet Neurol 6 765-772
[6]
Cox TM(2010)Long-term miglustat therapy in children with Niemann-Pick disease type C J Child Neurol 25 300-305
[7]
Lachmann RH(2010)Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial Mol Genet Metab 99 351-357
[8]
Hrebicek M(2009)Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study Mol Genet Metab 98 243-249
[9]
Platt FM(2011)Gastrointestinal disturbances and their management in miglustat-treated patients J Inherit Metab Dis 34 991-1001
[10]
Butters TD(2009)Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme Pharmacoepidemiol Drug Saf 18 770-777